what percent of americans are on glp 1 Big shift in U.S. health! A new Gallup poll shows 11% now taking GLP-1 drugs, coinciding with obesity rates dropping to 36.4% (down from 39.9% in 2022). Promising progress in Poll: 1 in 8 Adults

In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

GLP-1GLP-1GLP-1

Obesity affects 42% of adults in the United States and is strongly associated with major cardiovascular disease risk factors, including high blood pressure, abnormal cholesterol levels, and insulin resistance, making effective obesity treatment a critical public health priority.

G

Healthcare systems and benefit expectations vary by country, requiring multinational employers to balance global strategy with local implementation